Biotech

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔9/8/2020 8:28:54 AM

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small and Mid-Cap Conference 2020, a virtual conference.

Read Full Article

Anatara Lifesciences (ASX:ANR) ASX Small and Mid-Cap Conference 2020

🕔9/1/2020 11:33:08 AM

Steven Lydeamore, Chief Executive Officer, Anatara Lifesciences (ASX:ANR) will be presenting at the ASX Small and Mid-Cap Conference 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives Milestone Payment from Kyocera

🕔8/28/2020 10:06:35 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that is has received a payment of 100M JPY (~A$1.3M) from Kyocera Corporation (Kyocera, TYO:6971)

Read Full Article

Regeneus Ltd (ASX:RGS) To present at FNN Virtual Investor Event

🕔8/25/2020 11:39:09 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that its CEO Leo Lee, will present at the Finance News Network (FNN) CEO Showcase virtual event on Tuesday 25 August 2020 at 12:55pm (AEST). The event is primarily attended by Australian-based retail investors and advisors.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Financial Report 30 June 2020

🕔8/24/2020 3:08:51 PM

Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30 June 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent for Sygenus

🕔8/19/2020 9:26:38 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's Secretome technology platform, Sygenus, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) and Kyocera Sign Progenza OA Deal

🕔8/11/2020 9:51:25 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Kyocera Corporation (Kyocera, TYO:6971) has signed a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.

Read Full Article